Search
31/12/2025
Value contribution of trifluridine/tipiracil with bevacizumab for the treatment of metastatic colorectal cancer in Catalonia using a multicriteria decision analysis
Calle, C, Elez, E, Manzano, JL, Moreno-Martinez, ME, Pericay, C, Graefenhain, R, Ariznavarreta, A, Lizan, L. Value contribution of trifluridine/tipiracil with bevacizumab for the treatment of metastatic colorectal cancer in Catalonia using a multicriteria decision analysis. Journal Of Pharmaceutical Policy And Practice. 2025; 18(1)DOI:10.1080/20523211.2025.2567970. PMID:41415036. IF:(Q/D).
27/12/2025
Lipoprotein-Specific Fatty Acid Profiles in Familial Hypercholesterolemia: Associations with Cardiovascular History and Dietary Patterns
López-Yerena, A, Arroyo-Olivares, R, Santisteban, V, Muñoz-Garcia, N, Estruch, R, Mata, P, Badimon, L, Padro, T. Lipoprotein-Specific Fatty Acid Profiles in Familial Hypercholesterolemia: Associations with Cardiovascular History and Dietary Patterns. Nutrients. 2025; 18(1)DOI:10.3390/nu18010092. PMID:41515209. IF:5.000(Q1/2D).
25/12/2025
Ultrasound-Enhanced Assessment of Vitreous Status in Exudative AMD: Associations with Neovascular Phenotypes, Treatment Burden, and Functional Outcomes
Rodriguez-Vidal, C, Pandelo, LG, Martínez-Alday, N, Bande, M, Teijeiro, MJB. Ultrasound-Enhanced Assessment of Vitreous Status in Exudative AMD: Associations with Neovascular Phenotypes, Treatment Burden, and Functional Outcomes. Journal of Clinical Medicine. 2025; 15(1)DOI:10.3390/jcm15010167. PMID:41517415. IF:2.900(Q1/2D).
24/12/2025
PTH Analog Therapy in CKD G4-G5D: Current Evidence and Potential Role of Abaloparatide in Adynamic Bone Disease
Gifre, L, Fusaro, M, Lloret, MJ, Massó, E, Peris, P, Nogués, X, Gelpi, R, Prior-Español, A, Ara, J, Cozzolino, M, Ureña-Torres, PA, Bover, J. PTH Analog Therapy in CKD G4-G5D: Current Evidence and Potential Role of Abaloparatide in Adynamic Bone Disease. Journal of Clinical Medicine. 2025; 15(1)DOI:10.3390/jcm15010133. PMID:41517382. IF:2.900(Q1/2D).
23/12/2025
Characterizing Digital Communication Device Use Among Young People From 4 European Countries: Cross-Sectional Survey Study
Stamets, ML, Castaño-Vinyals, G, Viladoms, PD, Veludo, AF, Thielens, A, Martin, L, Wydaeghe, R, Aerts, S, Parazzini, M, Tognola, G, Wiart, J, Polanska, K, Popovic, M, López, MJ, Maule, M, Joseph, W, Grellier, J, Röösli, M, Guxens, M. Characterizing Digital Communication Device Use Among Young People From 4 European Countries: Cross-Sectional Survey Study. JOURNAL OF MEDICAL INTERNET RESEARCH. 2025; 27DOI:10.2196/76767. PMID:41432541. IF:6.000(Q1/1D).
23/12/2025
Short-Term Anticoagulation Versus Dual Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure: The ANDES Randomized Clinical Trial
Rodés-Cabau, J, Nombela-Franco, L, Cruz-Gonzalez, I, Hibbert, B, Freixa, X, Masson, JB, Ibrahim, R, Estevez-Loureiro, R, Millan, X, Kass, M, Paradis, JM, Champagne, J, Salinas, P, Laffond, A, Abdel-Razek, O, Labinaz, M, Cepas-Guillen, P, Arzamendi, D, Vidal-Cales, P, Pavesi, M, Côté, M, O'Hara, G, Salaun, E. Short-Term Anticoagulation Versus Dual Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure: The ANDES Randomized Clinical Trial. CIRCULATION. 2025; 152(25)DOI:10.1161/CIRCULATIONAHA.125.077469. PMID:41139402. IF:38.600(Q1/1D).
20/12/2025
A phase III placebo-controlled study of eftilagimod alfa plus pembrolizumab and chemotherapy in metastatic non-small cell lung cancer
O'Byrne, K, Esteban, E, Lee, CL, Hegmane, A, Volovat, C, Lo Russo, G, Ziogas, D, Atmaca, A, Sebastian, M, Majem, M. A phase III placebo-controlled study of eftilagimod alfa plus pembrolizumab and chemotherapy in metastatic non-small cell lung cancer. Future Oncology. 2025; 21(30)DOI:10.1080/14796694.2025.2597404. PMID:41383151. IF:2.600(Q3/6D).
19/12/2025
OAS1 and OAS3 genetic variants enhance inflammatory responses to SARS-CoV-2
DeDiego, ML, López-Fernández-Sobrino, R, Pedragosa, J, López-García, D, Nogales, A, Durbán, J, Cardona, F, Llucià-Carol, L, Rivero, V, Vazquez-Utrilla, P, Sanchez-Grande, LP, Cobo, M, Lloret, L, Márquez-Kisinousky, L, Ruiz-Jaén, F, Lozano, F, Sibila, O, Faner, R, Castro, P, Domingo, C, Robles, V, Bedini, JL, Rico, V, Aguero, D, Soriano, A, Nalda, AM, Martinez, AP, Colobran, R, Soler-Palacín, P, Serra-Llovich, A, Dietl, B, Arranz, MJ, Dalmau, D, Signes-Costa, J, Gil-Carbonell, J, Todolí, J, Martínez, J, Rojo, S, Fiz-López, A, Arribas, E, Cal-Sabater, P, Bernado, D, Vogel, M, Wiemann, S, Abolhassani, H, Pan-Hammarström, Q, Pujol, A, Su, HC, Lee, D, Zhang, SY, Casanova, JL, Fernández-Cadenas, I, Pérez-Tur, J, Planas, AM. OAS1 and OAS3 genetic variants enhance inflammatory responses to SARS-CoV-2. iScience. 2025; 28(12)DOI:10.1016/j.isci.2025.113966. PMID:41438061. IF:4.100(Q1/2D).
18/12/2025
Complications of Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-A Prospective Study on Behalf of the EBMT Transplant Complications Working Party
Tomaszewska, A, Basak, GW, Peczynski, C, Polge, E, Ambron, P, Boreland, W, Sica, S, Arat, M, Passweg, J, Lorenzo, JLL, Salmenniemi, U, Jindra, P, Kulagin, A, Bufarull, RM, Eder, M, Bekadja, MA, Mussetti, A, Graham, CE, Schoemans, H, Penack, O, Moiseev, I, Peric, Z. Complications of Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-A Prospective Study on Behalf of the EBMT Transplant Complications Working Party. Cancers. 2025; 17(24)DOI:10.3390/cancers17244029. PMID:41463278. IF:4.400(Q2/3D).
18/12/2025
Hydrogen-Rich Water Potentiates Cannabinoid- and Gabapentinoid-Induced Analgesia in Neuropathic Pain
Tort, NA, Negrini-Ferrari, SE, Pol, O. Hydrogen-Rich Water Potentiates Cannabinoid- and Gabapentinoid-Induced Analgesia in Neuropathic Pain. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2025; 26(24)DOI:10.3390/ijms262412155. PMID:41465581. IF:4.900(Q1/3D).
17/12/2025
Impact of arterial occlusion location on early neurological deterioration in patients with minor stroke treated with intravenous thrombolysis. The MINORCAT-END study
Font, MA, García-Sánchez, SM, Mengual, JJ, Avellaneda-Gomez, C, Boned, S, Aragonès, JM, Silva, Y, Martínez, M, Doncel-Moriano, A, Ustrell, X, Camps-Renom, P, Mauri-Capdevila, G, Purroy, F, Rodríguez-Campello, A, Palomeras, E, Krupinski, J, Figueras-Aguirre, G, Catena, E, García-Alhama, J, Esteve-Belloch, P, Matos, N, Colom, C, Aguilo, O, Coll, A, Díaz, G, Tio, E, Ortega, O, Alfonso, S, Jiménez-Fàbrega, X, Salvat-Plana, M, Elosua, R, de la Ossa, NP, Abilleira, S, Gomez-Choco, M. Impact of arterial occlusion location on early neurological deterioration in patients with minor stroke treated with intravenous thrombolysis. The MINORCAT-END study. NEUROLOGICAL SCIENCES. 2025; 47(1)DOI:10.1007/s10072-025-08721-7. PMID:41405770. IF:2.400(Q3/6D).
16/12/2025
Mortality and Non-Fatal Clinical Outcomes After the Most Common Cancers in People with HIV: A Multicohort Collaboration
Timiryasova, A, Greenberg, L, Domingo, P, Tarr, PE, Egle, A, Martin, C, Mussini, C, Wit, F, Cingolani, A, Lehmann, C, Castagna, A, Petoumenos, K, Sabin, CA, Bonnet, F, Lundgren, J, Bottanelli, M, Hosein, S, Carlander, C, Amstutz, A, Grabmeier-Pfistershammer, K, Garges, H, Marongiu, A, Young, LA, Peters, L, Ryom, L. Mortality and Non-Fatal Clinical Outcomes After the Most Common Cancers in People with HIV: A Multicohort Collaboration. Cancers. 2025; 17(24)DOI:10.3390/cancers17244000. PMID:41463249. IF:4.400(Q2/3D).
16/12/2025
Patient safety risk associated with synchronous telehealth: A scoping review
de Oliveira, JSR, Fernandez, RS, Molina, MR, Pinto, ACPN, Rocha, CR, Ferreira, TM, Peres, SV. Patient safety risk associated with synchronous telehealth: A scoping review. PLoS One. 2025; 20(12)DOI:10.1371/journal.pone.0336992. PMID:41401191. IF:2.600(Q2/4D).
16/12/2025
Development and Validation of the Sequential Organ Failure Assessment (SOFA)-2 Score
Ranzani, OT, Singer, M, Salluh, JIF, Shankar-Hari, M, Pilcher, D, Berger-Estilita, J, Coopersmith, CM, Juffermans, NP, Laffey, J, Reinikainen, M, Neto, AS, Tavares, M, Timsit, JF, Lopez, MDA, Arulkumaran, N, Aryal, D, Azoulay, E, Celi, LA, Chaudhuri, D, De Lange, D, De Waele, J, Dos Santos, CC, Du, B, Einav, S, Engelbrecht, T, Fazla, F, Ferrer, R, Finazzi, S, Fujii, T, Gershengorn, HB, Greene, JD, Haniffa, R, Hao, SC, Hasan, MS, Hollenberg, S, Ippolito, M, Jung, C, Kirov, M, Kobari, S, Lakbar, I, Lipman, J, Liu, V, Liu, XL, Lobo, SM, Magatti, D, Martin, GS, Metnitz, B, Metnitz, P, Myatra, SN, Oczkowski, S, Paiva, JA, Paruk, F, Pekkarinen, PT, Piquilloud, L, Pölkki, A, Prescott, HC, Blaser, AR, Rezende, E, Robba, C, Rochwerg, B, Ruckly, S, Samei, R, Schenck, EJ, Secombe, P, Sendagire, C, Siaw-Frimpong, M, Simpkin, AJ, Soares, M, Summers, C, Szczeklik, W, Takala, J, Tanaka, S, Tricella, G, Vincent, JL, Wendon, J, Zampieri, FG, Rhodes, A, Moreno, R. Development and Validation of the Sequential Organ Failure Assessment (SOFA)-2 Score. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. 2025; 334(23)DOI:10.1001/jama.2025.20516. PMID:41159833. IF:55.000(Q1/1D).
15/12/2025
Early start of opicapone in Parkinson's disease: evidence from a pooled analysis of phase 3 trials for sustained benefit in patients with recent onset of motor fluctuations
Ferreira, JJ, Stocchi, F, Antonini, A, Rascol, O, Ebersbach, G, Kulisevsky, J, Fonseca, MM, Ramos, D, Rocha, JF, Brigas, HC, Holenz, J, Poewe, W. Early start of opicapone in Parkinson's disease: evidence from a pooled analysis of phase 3 trials for sustained benefit in patients with recent onset of motor fluctuations. Frontiers in Neurology. 2025; 16DOI:10.3389/fneur.2025.1715748. PMID:41473225. IF:2.800(Q2/5D).
15/12/2025
Clinical and immunologic characteristics of nonhematologic autoimmune disorders in chronic lymphocytic leukemia
Arguello-Tomas, M, Lynton-Pons, E, Albiol, N, Lopez-Ferrer, A, Sierra, J, Moga, E, Moreno, C. Clinical and immunologic characteristics of nonhematologic autoimmune disorders in chronic lymphocytic leukemia. CANCER. 2025; 131(24)DOI:10.1002/cncr.70216. PMID:41378669. IF:5.100(Q1/3D).
15/12/2025
Ketamine, Etomidate, and Mortality in Emergency Department Intubations
Maia, IWA, Decker, SRR, Silva, LOJE, von Hellmann, R, Alencar, JCG, Hajjar, LA, de Carvalho, JMD, Pedrollo, DF, Nogueira, CG, Figueiredo, NMP, Miranda, CH, Martins, D, Baumgratz, TD, Bergesch, B, Colleoni, O, Zanettini, J, Freitas, AP, Tambelli, R, Costa, MC, Correia, W, de Maria, RG, , UAV, Weber, AP, Castro, VD, Dornelles, CFD, Tabach, BS, Moreira, NP, Gaspar, PL, Guimaraes, HP, Stanzani, G, Gava, TF, Mullan, A, Brown, CS, Bellolio, F, Jeffery, MM, Ranzani, OT, Besen, BAMP. Ketamine, Etomidate, and Mortality in Emergency Department Intubations. JAMA Network Open. 2025; 8(12)DOI:10.1001/jamanetworkopen.2025.48060. PMID:41396604. IF:9.700(Q1/1D).
14/12/2025
Targeting Overtreatment of Asymptomatic Bacteriuria in the Emergency Department: Results from a Quasi-Experimental Clinical Pharmacist-Led Program Based on Education and Audit
Monje, A, Escolà-Vergé, L, Rivera, A, Herrera, S, Plaza, A, Duch-Llorach, P, Pomar, V, Roch, N, Rouras, L, Lopez-Contreras, J, Ramos, JR. Targeting Overtreatment of Asymptomatic Bacteriuria in the Emergency Department: Results from a Quasi-Experimental Clinical Pharmacist-Led Program Based on Education and Audit. Antibiotics-Basel. 2025; 14(12)DOI:10.3390/antibiotics14121261. PMID:41463763. IF:4.600(Q1/2D).
12/12/2025
Clinical recognition of frontotemporal dementia with right temporal predominance: a consensus statement from the International Working Group
Ulugut, H, Younes, K, Montembeault, M, Bertoux, M, Irish, M, Kumfor, F, Fumagalli, GG, Samanci, B, Illán-Gala, I, Thompson, JC, Santillo, AF, Englund, E, Waldö, ML, Riedl, L, van den Stock, J, Vandenbulcke, M, Vandenberghe, R, Laforce, R, Ducharme, S, Pressman, PS, Caramelli, P, de Souza, LC, Takada, LT, Gurvit, H, Diehl-Schmid, J, Galimberti, D, Pasquier, F, Weintraub, S, Miller, BL, Sturm, VE, Whitwell, JL, Boeve, B, Rohrer, JD, Piguet, O, Gorno-Tempini, ML, Josephs, KA, Snowden, J, Rowe, JB, Warren, JD, Rankin, KP, Pijnenburg, YAL. Clinical recognition of frontotemporal dementia with right temporal predominance: a consensus statement from the International Working Group. Communications Medicine. 2025; 5(1)DOI:10.1038/s43856-025-01252-4. PMID:41387629. IF:(Q/D).
11/12/2025
Targeting Atherosclerosis: Cholesterol-Lowering Therapies with a New Immunometabolic Dress for an Old Disease
Julve, J, Rodriguez-Calvo, R, Perret, B, Martinez, LO, Mauricio, D. Targeting Atherosclerosis: Cholesterol-Lowering Therapies with a New Immunometabolic Dress for an Old Disease. Journal of Clinical Medicine. 2025; 14(24)DOI:10.3390/jcm14248777. PMID:41464678. IF:2.900(Q1/2D).